BAP1 Genotype

Most conversations about inherited cancer risk revolve around breast, ovarian, or colon cancer. This gene covers a rarer but serious cluster: melanoma of the eye, a cancer of the tissue lining the organs called mesothelioma, kidney cancer, and skin melanoma. If those cancers show up in your family, this is the gene worth checking.

This test reads the specific inherited spelling of your BAP1 (BRCA1-associated protein 1) gene. A faulty copy does not mean cancer is certain, but it places you in a high-risk group where earlier and more frequent screening genuinely changes what your doctors watch for.

What This Gene Normally Does

Your cells carry proteins whose job is to keep growth in check and repair damaged DNA. The BAP1 gene builds one of them: a protein that removes molecular tags from other proteins to help control which genes switch on and off. When both copies of the gene work, this system quietly restrains tumor formation.

You inherit one copy from each parent. People with BAP1 tumor predisposition syndrome are born with one faulty copy in every cell. If the second copy is later damaged in a single cell, that cell loses its brake entirely, which is how tumors begin. This is why the risk is inherited and lifelong rather than something that develops from lifestyle alone.

The Core Cancer Cluster

Germline (inherited) faults in BAP1 cause an autosomal dominant syndrome, meaning a single faulty copy is enough to raise risk and each child of a carrier has a one in two chance of inheriting it. The condition has a well-defined core group of cancers that appear again and again across families worldwide.

In a review of 215 reported carriers, the most common cancers were eye melanoma at 28%, mesothelioma at 22%, skin melanoma at 18%, and kidney cancer at 9%. The largest worldwide collection identified 181 families carrying 140 different faulty versions of the gene, and these faults were spread across the whole gene rather than clustered in one spot, so there is no single change to look for.

Eye Melanoma

Melanoma of the eye, known as uveal melanoma, is one of the strongest signals of this syndrome. Among people who carry a faulty BAP1 gene, the estimated chance of having eye melanoma is about 2.8% (95% confidence interval 0.88% to 4.81%), and carriers tend to be diagnosed younger, at a median of 50.5 years versus 63 years in the general population.

Carriers are also more likely to have the aggressive, spreading form of eye melanoma. In one study, faulty germline BAP1 turned up in 4 of 50 people whose ocular melanoma had spread, versus none of 50 whose cancer had not. Even so, most people with eye melanoma do not carry an inherited fault, so this gene explains only a slice of cases.

Mesothelioma

Mesothelioma is a cancer of the thin lining around the lungs and abdomen, usually tied to asbestos. In carriers it can appear at younger ages and with far less asbestos exposure than usual. In a Finnish group of mesothelioma patients, an inherited BAP1 fault was found in 1.8% of cases, close to the frequency seen in Finnish eye melanoma patients.

Here is a result that surprises many carriers, so it is worth resolving directly. Even though a BAP1 fault raises the chance of getting mesothelioma, carriers who develop it often survive longer than people with the usual asbestos-driven form, and their tumors can behave more slowly. These findings are not in conflict. Carrying the gene is a risk marker for developing cancer, not a stamp of a worse outcome once cancer appears, and carrier tumors are often caught earlier and grow less aggressively.

Kidney Cancer

Clear-cell kidney cancer is a core part of the syndrome, and BAP1 loss tends to mark more aggressive kidney tumors. This is why carriers benefit from periodic imaging of the kidneys rather than waiting for symptoms, since these cancers can grow silently before they cause pain or blood in the urine.

Telltale Skin and Nail Signs

One of the most useful outward clues is a distinctive type of skin bump. These lesions, sometimes called BAP1-inactivated melanocytic tumors, look like raised, skin-colored or reddish mole-like growths. In one review, they appeared in 75% of carriers who had a full-body skin examination, often before any internal cancer developed. Some carriers are also recognized through nail changes.

A single such bump on its own is a weak signal, but several of them, or one alongside a personal or family history of the core cancers, sharply raises the chance of carrying an inherited fault. This is why dermatologists are often the first to suspect the syndrome.

A Separate Childhood Syndrome

A different and much rarer set of BAP1 changes has a completely different effect. Certain spontaneous single-letter changes (missense variants) that arise newly in a child, rather than being inherited, cause a syndromic neurodevelopmental disorder rather than the cancer syndrome. This matters because it shows that not every BAP1 change means the same thing, and the exact variant determines the consequence.

Not Everyone With a Variant Gets Cancer

Carrying a faulty BAP1 gene raises risk substantially, but it does not guarantee cancer, and the odds change with age. In large family studies, the share of carriers who were still cancer-free fell from 74% at ages 20 to 29 to 7% by ages 60 to 69. The type of fault also matters: variants that completely switch off the gene tend to cause cancers at younger ages than milder single-letter changes.

One caution about these numbers: they come mostly from families identified because they already had many cancers, which tends to make the risk look higher than it is for an average carrier. Population-based studies suggest a more moderate picture. A positive result should be read as a strong reason to screen carefully, not as a prediction that cancer is inevitable.

Why This Is a One-Time Test

Your BAP1 genotype is fixed at conception and does not change over your life, so this is a once-in-a-lifetime test. There is no trend to track and no reason to repeat it, unless a laboratory recommends confirming an uncertain result with a second method. The value of the result comes entirely from what you do with it over the following years, not from retesting.

What does need ongoing attention is the screening the result unlocks. If you carry a fault, the practical follow-up is a repeating cycle of surveillance, discussed below, rather than another genetic test. Think of the genotype as the one-time key that determines how closely the rest of your body should be watched.

What to Do With a Positive Result

A positive or uncertain result is a starting point for a specific workup, not a diagnosis. The most useful next steps are consistent across the evidence:

• Confirm and interpret with a specialist: a genetic counselor or clinical geneticist can confirm the variant, sometimes with a second lab method, and tell you whether it is clearly harmful, uncertain, or benign.
• Start targeted surveillance: carriers are generally offered regular dilated eye exams, full-body skin checks by a dermatologist, and periodic imaging of the kidneys and abdomen, often using MRI to limit radiation exposure.
• Reduce avoidable exposures: because the linked cancers are sensitive to asbestos, sun, and radiation, minimizing those exposures is a reasonable step for carriers.
• Talk to your biological relatives: parents, siblings, and children each have a meaningful chance of carrying the same fault, and cascade testing lets them access the same screening or be reassured they did not inherit it.

The combination that most warrants action is a convincingly harmful variant plus any personal or family history of the core cancers. An uncertain variant with no supporting history usually calls for watchful monitoring and expert review rather than aggressive intervention.

When a Genetic Result Can Mislead

A genetic result carries its own pitfalls, and knowing them keeps you from over- or under-reacting:

• Panel coverage: this test detects only the specific variants it is designed to find, so a negative result does not rule out every possible change in BAP1 or in other cancer-risk genes.
• Uncertain variants: some results come back as a variant of uncertain significance, meaning a change was found but its effect is not yet known. Functional lab work is steadily reclassifying these, and one recurring splice variant once thought harmful was downgraded to uncertain after closer study.
• Tumor versus inherited: a BAP1 result from a tumor sample or a tumor stain (immunohistochemistry) reflects the cancer, not necessarily your inherited status, and tumor-only testing can misclassify an inherited fault as one confined to the tumor.
• Ancestry and assay quality: the meaning and frequency of specific variants can differ by ancestry, and a clinical-grade genetic test is more reliable than a consumer ancestry report for a medical decision this important.